Skip to content
etf.net

Launched · SEC filings

ProShares Ultra Nasdaq Biotechnology

BIBNasdaqProSharesBThis fund multiplies its index's move each day and resets that multiple daily. Because daily returns compound, its long-run return can differ from the headline multiple.

$117.10−3.43 (−2.85%)

At close: Nov 2, 2026, 4:00 PM ET

B64/ 100

Rank 8 of 99 in Leveraged Long (2x & Other)

B64/100Rank 8 of 99inLeveraged Long (2x & Other)
Intraday session: down, 79 prints from 120.53 to 117.10. Range 116.97 to 121.27. Use the arrow keys to read each point.118.00119.00120.0010 AM12 PM2 PM4 PM
Expense ratio
0.95%*
Fund size
$104M
1Y total return
+68.9%
Yield · Last 12 months
0.19%
Holdings
247
Avg volume · 30D
10.5K sh
52W range
low $67.50high $126.40
Launched
Filings
SEC EDGAR

*After a fee waiver that ends Sep 30, 2027. Without it: 1.17%.

The ETF.net BIB Grade

Based on 5 of 6 pillars

B

Score 64 out of 100

Category
Leveraged Long (2x & Other)⁠
Rank
8 of 99
Six-pillar profile for BIB. Scores out of 100: Cost 51, Risk 70, Mission not scored, Tradability 84, Holdings 60, Durability 75. Strongest: Tradability (84). Weakest: Cost (51). Based on 5 of 6 pillars.

Score 64 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    C51 out of 100
    Rank 32 of 99

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    Not scored

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    A70 out of 100
    Rank 20 of 98

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    A84 out of 100
    Rank 7 of 99

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    B60 out of 100
    Rank 11 of 27

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    A75 out of 100
    Rank 11 of 99

Our read on BIB

ETF.net Research

In short

BBiotech with the dial at 2x, not 3x. Since 2010 BIB has aimed at twice the daily move of the Nasdaq Biotechnology Index, a modified cap-weighted set of Nasdaq-listed biotech and pharma names, reset fresh every single day.

Stated mandate

The Fund seeks daily investment results, before fees and expenses, that correspond to two times the daily performance of the Nasdaq Biotechnology Index.

Why people hold it

  • Aims for two times the daily move of the Nasdaq Biotechnology Index. Magnified biotech exposure through one ticker in a regular brokerage account, no margin agreement needed.proshares.com
  • The benchmark dates to 1993: Nasdaq-listed biotech and pharma, modified cap-weighted, roughly 300 stocks. Industry-wide exposure, not a handful of lottery tickets.nasdaqomx.comnasdaqomx.com 2
  • 0.95% net of a waiver through September 30, 2027, against a 1.17% gross. Near the category median and level with ProShares stablemate DDM at 0.95%.
  • Live since 2010 through several biotech boom-and-bust cycles, and it stands among the stronger implementations in a crowded leveraged-bull field.

Worth knowing

  • Daily reset. Hold past one day and compounding takes over: returns can differ in amount, and even direction, from 2x the index over that stretch.proshares.com
  • One industry, doubled. Trial readouts and FDA decisions move biotech hard, and this fund is built to amplify those days in both directions.proshares.com
  • Among the lighter-traded, smaller funds in its category, so spreads and order size matter more here than with the headline leveraged names.

BIB Performance

Launched Apr 7, 2010

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

BIB$16,894
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. BIB $16,894. SPY $11,199. Use the arrow keys to read each point.$10,000$12,500$15,000$17,500Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for BIB. Periods over one year show the average yearly return.
PeriodBIB
Year to date+51.2%
1 month+4.4%
3 months+24.9%
1 year+68.9%
3 yearsper year+43.9%
5 yearsper year+6.4%
10 yearsper year+12.6%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for BIB
YearReturn barBIB
2026 YTD+51.2%
2025+59.2%
2024−9.8%
2023−1.1%
2022−28.8%

BIB in the news

BIB Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
0.19%Last 12 months
Payout per share
$0.22Last 12 months
Last payment
$0.08 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Twice a year

Distribution history

2017–2026

One bar per payment. 12 payments from 2017 to 2026 YTD. Dec 22, 2022 $0.02; Dec 20, 2023 $0.04; Mar 20, 2024 $0.04; Jun 26, 2024 $0.26; Sep 25, 2024 $0.15; Dec 23, 2024 $0.40; Mar 26, 2025 $0.13; Jun 25, 2025 $0.17; Sep 24, 2025 $0.18; Dec 24, 2025 $0.13; Mar 25, 2026 $0.0071; Sep 23, 2026 $0.08. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Sep 23, 2026Sep 29, 2026$0.08
Mar 25, 2026Mar 31, 2026$0.0071
Dec 24, 2025Dec 31, 2025$0.13
Sep 24, 2025Sep 30, 2025$0.18
Jun 25, 2025Jul 1, 2025$0.17
Mar 26, 2025Apr 1, 2025$0.13
Dec 23, 2024Dec 31, 2024$0.40
Sep 25, 2024Oct 2, 2024$0.15
Jun 26, 2024Jul 3, 2024$0.26
Mar 20, 2024Mar 27, 2024$0.04
Dec 20, 2023Dec 28, 2023$0.04
Dec 22, 2022Dec 30, 2022$0.02

See all 13 payments⁠

$10,000 in BIB 10 years ago paid $444 in dividends.⁠

BIB Risk

Risk pillarA70 out of 100Rank 20 of 98 in Leveraged Long (2x & Other)

This fund targets a multiple of the daily move of its index and resets daily. Hold it longer than one reset and compounding makes the return diverge from that target. In choppy markets it can lose value even when the index ends flat.

How much the fund’s monthly returns vary, scaled to a year.
33.9%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.12
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−61.8%
Trough Apr 2025
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
1.20
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

BIB Cost

Compare BIB and WX

Overpaying vs WX, cheapest in Leveraged Long (2x & Other)

$13,714

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BIB 0.95%

    $17,869

  • WX 0.20% Cheapest

    $4,155

$10,000
30 years

Cost over time

  • BIB 0.95%
  • WX 0.20%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$5K$10K$15K$20K051015202530BIB $17,869WX $4,155

Year by year

YearBIBWXOverpaying
10$1,678$365$1,313
20$6,322$1,421$4,901
30$17,869$4,155$13,714
How the 0.95% is worked out

Full fee 1.17%− waiver 0.22%= you pay 0.95%

The waiver ends Sep 30, 2027. After that the fee is 1.17% unless ProShares renews it. Source: prospectus, Sep 2026.

Other funds in Leveraged Long (2x & Other)

See others